For example, the METLUNG trial is evaluating EGFR-mutant NSCLC patients on EGFR tyrosine kinase inhibitors ± metformin (312 patients, Stage IIIB-IV) to see if metformin prolongs PFS [96,99]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.